Tag: NIH license
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Circular beds: Revolutionising sustainable bedding in Australia
A new wave of innovation is transforming the Australian manufacturing sector, with sustainability at its core. ROBOVOID, in collaboration with Swinburne University, GT Recycling, and Sustainability Victoria, has developed a groundbreaking bed base made entirely from recycled plastic.
